Osmind

We are excited to announce a landmark collaboration with the American Psychiatric Association (APA) to advance quality psychiatric care and accelerate research. "At Osmind, we emphasize the importance of clinicians participating in evidence-generating medicine to help shape the future of mental health care, especially as the psychiatric field begins to embrace new treatments and precision psychiatry,” says Carlene MacMillan, MD, Chief Medical Officer of Osmind. “Clinicians in private practice juggle many competing demands so it is crucial we make participation both easy and worthwhile to them." To make participation in evidence-generating medicine easier for busy private practitioners, we’re integrating APA's diagnostic and outcomes measures directly into the Osmind EHR. We're starting with the DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure, which joins our library of 40+ measures, enabling clinicians to contribute to research at the point of care. We’ll also explore an integration between the Osmind EHR and PsychPRO so that clinicians using the Osmind EHR can participate effortlessly in the PsychPRO registry. "PsychPRO is the tool healthcare organizations need to guide their efforts to deliver quality mental health care and improve patient outcomes," says Nitin Gogtay, M.D., APA Chief of Research and Deputy Medical Director. "Our collaboration with Osmind will allow us to strengthen PsychPRO today, and long-term offers promise to broaden the scope of our impact on psychiatry and on the patients we serve.” We are delighted to work with the APA, and proud to enable independent practices to contribute to the evolution of the field and elevate their own evidence-based practices. https://lnkd.in/g4RU7Ftt

Great analysis on MDMA-AT and the FDA from our Vice President of Scientific Affairs, L. Alison McInnes MD, MS!

The mental health world is on edge as we await the FDA's verdict on MDMA-assisted therapy for PTSD. But what's really at stake? In our latest Psychiatry Tomorrow podcast, Carlene MacMillan, MD, FCTMSS, DFAACAP sat down with experts Owen Muir MD DFAACAP, Boris Heifets, M.D, PhD, and Andrew Penn, RN, NP, CNS, PMHNP-BC to unpack this pivotal moment in psychiatry. We dove deep into: -The tug-of-war between clinical enthusiasm and regulatory caution (+ clinician survey results) -How to think about "functional unblinding" in MDMA and psychedelic trials -Safety and long-term outcomes to safeguard MDMA -Who's qualified to guide these transformative experiences? -What does the future hold for other psychedelic treatments? Plus, we tackled the million-dollar question: Will the FDA give the green light?🚦 Whether you're a mental health clinician, researcher, or just curious about the future of PTSD treatment, this episode is a must-listen. Tune in or read the summary of the discussion below. Or, search “Psychiatry Tomorrow” on your favorite podcast player. What are your thoughts on MDMA-assisted therapy and the FDA’s decision? Share below! 👇 https://lnkd.in/drJyK2xh

It was so much fun to revisit the dawning of the golden era of psychiatry in the aughts. There had been no antidepressant therapies with a novel mechanism of action for over 60 years till TMS and ketamine emerged. David was an enthusiastic early adopter. These therapies have encouraged advances in neurostimulation and a renewed interest in developing medications for psychiatric disorders. David is a passionate advocate for insurance coverage for ketamine and for using ketamine for PTSD in underserved populations. Enjoy! David Feifel, MD, PhDOsmind

What do quantum physics and breakthrough psychiatric treatments have in common? Enter the golden era of psychiatry with David Feifel, MD, PhD. In our latest Psychiatry Tomorrow episode, Dr. Feifel shares how following his curiosity led him to surprising places: breakthrough treatments in a cancer center, academia at UCSD, private practice at Kadima Neuropsychiatry Institute, and abroad in Rwanda. You'll learn: -How Dr. Feifel’s curiosity with quantum physics sparked an unconventional path in psychiatry -How a cancer center unlocked an epiphany about set and setting -How combining cutting-edge therapies changes outcomes for treatment-resistant patients -The complex battle for insurance coverage of breakthrough treatments -Expanding innovative psychiatric care globally - from San Diego to Rwanda Ready to explore the future of psychiatry? 🎧 Read or listen to the interview with the link below. Or, search for "Psychiatry Tomorrow" on your favorite podcast app. https://lnkd.in/dVEubgx3

Congrats to Osmind Community Advisory Board members Tobias Marton MD, PhD and Richard Bermudes, M.D. on their important new study on TMS! The study showed that TMS was highly effective, but underutilized and restricted to more treatment-resistant patients, largely due to the restrictive payor criteria for TMS coverage at that time. This research highlights the urgent need to align payor criteria with current evidence. Doing so could expand TMS adoption and improve outcomes for depression patients. Kudos to Richard Bermudes, M.D., Tobias Marton MD, PhD, Mindful Health Solutions, and everyone fueling our mission to empower clinicians and researchers in bringing innovative mental health treatments to those who need them most. Together, we're paving the way for more accessible, effective mental health care.

📊 The World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) is your quick functional assessment in psychiatry. Bookmark this quick reference guide and free score calculator: - History and development by WHO - 6 key domains of functioning assessed - Scoring and interpretation - Integration with DSM-5 for impairment assessment - Practical applications in clinical settings - Real-world case studies 🧮 Plus, try our free interactive WHODAS 2.0 score calculator for instant results and interpretations! Elevate your practice with evidence-based care: https://bit.ly/3Y66zFR

📊 The Generalized Anxiety Disorder-7 (GAD-7) is a cornerstone of anxiety assessment in psychiatry. It's essential to your Measurement-Based Care toolkit. Bookmark this quick reference guide: -Origins and development of the GAD-7 -Scoring system and interpretation guidelines -Psychometric strengths -Practical implementation in clinical practice -Real-world case studies showing its impact on treatment decisions -🧮 Plus, try our free interactive GAD-7 score calculator for instant results and interpretations! https://lnkd.in/dK-PYjwS

We're excited to announce Husseini Manji, M.D., F.R.C.P.C., a pioneering neuroscience leader who previously served as Global Head of Neuroscience at Janssen, has joined Osmind as a Strategic Advisor. Dr. Manji is renowned for bringing breakthrough, rapid-acting treatments to market, including esketamine (SPRAVATO®) for depression. His work has reconceptualized our understanding of severe neuropsychiatric disorders as genetically influenced disorders of synaptic and neural plasticity, leading to groundbreaking therapeutics. "I am excited to be a Strategic Advisor at Osmind, which is doing important, much-needed work. I truly believe that we are at an inflection point in our ability to markedly improve outcomes for our patients – both from an improved understanding of novel therapeutics, and our ability to move towards precision medicine." - Dr. Manji As the current Chair of the UK Government Mental Health Mission, Dr. Manji brings unparalleled expertise in developing treatments for neurologic, psychiatric, and pain-related disorders with high unmet needs. His insights will be crucial in advancing Osmind's research initiatives and supporting the development of innovative mental health treatments. Read the full announcement: https://lnkd.in/daVnnKcR

I'm looking for someone to join me on our remote Care Team at Osmind. We have an opening for a Full Stack Software Engineer who wants to have a meaningful impact. Our vision is to build a platform so every person with mental health conditions can find a treatment that works for them. Osmind is the premier EHR for clinicians and researchers advancing new life-saving mental health treatments. If this role sounds interesting, please apply here: https://lnkd.in/gjf33FGw